Content available at: https://www.ipinnovative.com/open-access-journals

Southeast Asian Journal of Health Professional

Journal homepage: https://www.sajhp.com/

Review Article

Innovations in ocular drug delivery

Sumit Goyal[1]*, Pranjali Dwivedi[2], Jaya Kaushik[3], Mayank Jhanwar[4], Ankita Singh[5], Anushree C M[6]

[1]*Dept. of Ophthalmology, Military Hospital, Bareilly, Uttar Pardesh, India*
[2]*Dept. of Obstetrics and Gynaecology, Military Hospital, Bareilly, Uttar Pradesh, India*
[3]*Dept. of Ophthalmology, Command Hospital, Lucknow, Uttar Pradesh, India*
[4]*Dept. of Ophthalmology, INHS Sanjivani, Kochi, Kerala, India*
[5]*Dept. of Ophthalmology,, Military Hospital, Bathinda, Punjab, India*
[6]*Dept. of Ophthalmology, Military Hospital, Agra, Uttar Pradesh, India*

ARTICLE INFO

Article history:
Received 25-08-2024
Accepted 16-09-2024
Available online 04-10-2024

Keywords:
Ocular drug delivery
Nanotechnology
Implants
Hydrogels
Microneedle
Gene-therapy

ABSTRACT

Background: Traditional ocular drug delivery methods via topical (eye drops and ointments) and systemic routes (oral or intravenous medications) yield suboptimal therapeutic drug concentrations intraocularly. Innovations aimed at improving the localization, duration, and efficacy of ocular drug delivery have shifted treatment paradigm by enhancing drug penetration, sustaining drug release and also enhancing patient compliance.

Materials and Methods: Aim of this review is to summarize recent advancements in ocular drug delivery systems, to evaluate their clinical effectiveness and to discuss their potential to improve clinical outcomes. The review will also identify ongoing challenges and future research avenues leading to further progress in this field.

Results: Recent advancements in ocular drug delivery systems are based on Nanotechnology-based delivery systems; Sustained-release implants and devices; Hydrogels and contact lens; Microneedle technology and Gene therapy vectors. Nanoparticles, nanomicelles, and nanoemulsions improve drug penetration and provide sustained release within ocular tissues. Biodegradable and non-biodegradable implants and devices offer prolonged drug delivery. Hydrogels and drug-embedded contact lenses improved patient comfort. Microneedle arrays enabling minimally invasive drug delivery directly to ocular tissues. Viral and non-viral vectors address underlying genetic causes in inherited retinal diseases.

Conclusion: Traditional methods such as eye drops, ointments, and intravitreal injections have limitations, including poor bioavailability, frequent administration, and non-compliance. Emergence of novel delivery systems, including nanoparticles, microneedles, sustained-release implants, and gene therapy vectors, offers solutions to these challenges. These innovations provide controlled and sustained drug release, improved drug stability, and targeted delivery to specific ocular tissues, resulting in enhanced therapeutic outcomes and reduced side effects.

1. Introduction

Ocular diseases represent a significant public health concern, contributing to considerable morbidity and impaired quality of life. Conditions such as glaucoma, age-

* *Corresponding author.*
E-mail address: sumit.2591 @gmail.com (S. Goyal).

https://doi.org/10.18231/j.sajhp.2024.015

related macular degeneration (AMD), diabetic retinopathy, and infectious or inflammatory ocular disorders impose challenges in terms of effective treatment and management. Traditionally, ocular drug delivery has relied upon topical administration (eye drops and ointments) and systemic routes (oral or intravenous medications). Despite their widespread use, these conventional methods often yield suboptimal therapeutic drug concentrations intraocularly. The unique anatomical and physiological characteristics of the eye present barriers hindering the delivery and efficacy of therapeutic agents intended for ocular diseases due to several factors. The corneal epithelium is lipophilic, making it difficult for hydrophilic drugs to penetrate. The blood-retinal and blood-aqueous barriers restrict drugs entry from systemic circulation to the ocular tissues. Frequent administration of topical drugs is necessitated as rapid clearing of drugs occurs from ocular surface due to tear turnover, blinking, and nasolacrimal drainage.

2. Aim

In recent years, the field of ocular drug delivery has seen phenomenal innovations aimed at improving the localization, duration, and efficacy of drug delivery. These developments have great potential to shift the treatment paradigm for various ocular ailments by enhancing drug penetration, sustaining drug release and also enhancing patient compliance. The aim of this review is to summarize recent advancements in ocular drug delivery systems. To cite a few, we will focus on recent development in:

1. **Nanotechnology:** Based Delivery Systems: Including nanoparticles, nanomicelles, and nanoemulsions designed to improve drug penetration and provide sustained release within the ocular tissues.
2. **Sustained:** Release Implants and Devices: Such as biodegradable and non-biodegradable implants and devices, which offer prolonged drug delivery and reduced dosing frequency.
3. **Hydrogels and contact lens:** Based Delivery: Emerging technologies utilizing hydrogels and drug-embedded contact lenses for continuous drug release and improved patient comfort.
4. **Microneedle technology:** Innovative microneedle arrays enabling minimally invasive drug delivery directly to ocular tissues, circumventing traditional barriers.
5. **Gene therapy vectors:** Recent advancements in viral and non-viral vectors for gene therapy in inherited retinal diseases, addressing the underlying genetic causes.

The aim of this review is therefore to systematically report these recent advances, to evaluate their clinical effectiveness and to discuss their potential to improve clinical patient outcomes. The review will also identify the ongoing challenges and future research avenues leading to further progress in this field.

3. Discussion

3.1. Traditional ocular drug delivery methods

Traditional methods have been widely used but often come with limitations that hinder effective treatment.

3.1.1. Topical administration

Topical delivery to the eye, in the form of eye drops and ointments, is the most widely employed route. It is the preferred route for ocular drug delivery to treat conditions such as conjunctivitis, keratitis and glaucoma as it is easy to administer and well accepted by patients. But this route has the following limitations:

a).**Low bioavailability:** Following administration of eye drops, the bioavailability of the drug is generally reported to be less than 5%. This is due to natural barriers of the eye such as corneal epithelium and tear film. In addition, the rapid turnover of tears and blinking action also minimizes the retention of drug on ocular surface.

b).**Frequent dosing:** To attain therapeutic levels, frequent dosing is usually required (e.g. Dorzolamide for glaucoma). This may result in poor patient compliance for chronic diseases.

c).**Systemic absorption:** Drug absorbed from the eye into the systemic circulation through the nasolacrimal duct may result in unwanted systemic side effects.

3.1.2. Systemic administration

The drugs are administered orally or intravenously for the treatment of ocular diseases. This approach is generally employed for posterior segment disorders of eye such as diabetic retinopathy and uveitis. Systemic administration of drugs has certain limitations:

a).**Blood-ocular barriers:** The blood-retinal and blood-aqueous barriers restrict the influx of drugs to ocular tissues to a great extent, which necessitate the requirement of a higher dose leading to systemic side effects.

b).**Adverse effects:** A higher systemic dose (to achieve the therapeutic drug concentration in the eye) may cause severe side effects in other organs and tissues.

c).**Delayed therapeutic action:** The onset of action is delayed which is not suitable for acute conditions where immediate treatment is necessitated

3.1.3. Periocular and intraocular injections

To overcome few limitations of topical and systemic routes, drugs can be administered via periocular (subconjunctival, sub-Tenon and peribulbar injections) and intraocular (intravitreal injections) routes. Periocular injections deliver drugs into the tissue around the eye, whereas intraocular injections deliver drugs directly into the eye.

a).**Periocular injections:** These injections place the drugs into the periocular tissues achieving high local concentrations and minimizing systemic exposure. Periocular injections are employed for posterior uveitis, cystoid macular edema etc. However, this route of drug administration causes discomfort to the patient and also has the risks of infection, local tissue necrosis etc.

b).**Intraocular injections**: In intravitreal injections, drugs are injected directly into the vitreous humor. This route gives high local concentrations and is used to treat the posterior segment diseases such as AMD, diabetic retinopathy etc. Although very effective, these injections are an invasive procedure with potential complications like endophthalmitis, retinal detachment, and vitreous haemorrhage. The need for repeated injections can also be burdensome for patients.

In summary, while traditional methods have been the cornerstone of ocular drug delivery, their limitations highlight the need for innovative approaches to enhance therapeutic outcomes. The next sections of this review will explore recent advancements in ocular drug delivery systems designed to address these challenges and improve patient care.

3.2. Newer innovations and clinical applications

These advanced methods aim to overcome the limitations of traditional methods by enhancing drug bioavailability, reducing dosing frequency, and improving patient compliance. The section will explore several key innovations in ocular drug delivery.

3.2.1. Nanotechnology-based delivery systems

Nanotechnology has emerged as a promising approach in ocular drug delivery, offering enhanced drug penetration and sustained release profiles. Various nanocarriers, including nanoparticles, nanomicelles, and nanoemulsions, are being developed for ocular applications.

a).**Nanoparticles:** Nanoparticles, typically ranging from 1 to 100 nm, can encapsulate drugs, enhancing their stability and bioavailability. They facilitate targeted delivery and controlled release, reducing systemic side effects. For example, polymeric nanoparticles have been used to deliver anti-glaucoma drugs, with better intraocular pressure (IOP) reduction and prolonged therapeutic effects. Nanoparticles have been used to deliver anti-VEGF (vascular endothelial growth factor) therapies directly to the retina, providing sustained release and reducing the frequency of intravitreal injections in AMD. Bhatt P, et al reported that thermo-reversible gel formulation containing Sunitinib nanoparticles can maintain therapeutic drug levels for extended periods, resulting in improved visual acuity and reduced retinal thickness in patients with AMD.[1]

b).**Nanomicelles:** These are self-assembling colloidal dispersions formed by amphiphilic molecules. Nanomicelles improve the solubility of hydrophobic drugs and enhance their ocular absorption. Studies have demonstrated that nanomicelle formulations can increase the bioavailability of poorly soluble drugs, offering a sustained release mechanism. These formulations have been explored for delivering anti-glaucoma drugs. They enhance drug solubility and penetration, leading to better intraocular pressure (IOP) control. Dal Monte M, et al reported the hypotensive effect of nanomicellar formulation of melatonin and agomelatine in a rat model.[2]

c).**Nanoemulsions:** Nanoemulsions are fine oil-in-water or water-in-oil dispersions stabilized by surfactants. They provide a stable medium for drug delivery, enhancing drug penetration through the cornea and other ocular tissues. Nanoemulsions have been used effectively to deliver anti-inflammatory and anti-infective agents in the treatment of anterior segment diseases. These formulations have been effectively used to treat anterior segment infections, such as bacterial keratitis. They provide enhanced drug stability and penetration, leading to faster resolution of infections and reduced inflammation.[3]

3.2.2. Sustained-Release implants and devices

Sustained-release implants and devices offer a means to deliver drugs over extended periods minimizing the need for frequent dosing, thereby improving patient adherence.

a).Non-Biodegradable implants

Non-biodegradable implants, such as the fluocinolone acetonide implant (Retisert), deliver drugs over several years. They are surgically implanted and can be replaced or removed if necessary. These implants have shown efficacy in treating chronic posterior non-infectious uveitis and other long-term inflammatory conditions. Studies have shown that Retisert can control inflammation for up to three years, significantly reducing the frequency of uveitis flares and improving visual outcomes.[4]

b).Biodegradable implants

These implants gradually degrade in the ocular environment, releasing the drug over a controlled period. An example is the dexamethasone intravitreal implant (Ozurdex), which provides sustained anti-inflammatory effects for up to six months. This implant has been widely used to treat Diabetic Macular Edema (DME). Clinical trials have demonstrated that Ozurdex provides sustained improvement in visual acuity and retinal thickness over several months, reducing the need for repeated intravitreal injections.[5]

c).Microelectromechanical systems (MEMS)

MEMS-based devices are miniaturized mechanical systems that can be implanted in the eye to deliver precise doses of drugs at programmed intervals. These systems offer the potential for highly controlled and customizable drug delivery, improving therapeutic outcomes. MEMS devices are being investigated for delivering precise doses of drugs

to the posterior segment. Early clinical results indicate that MEMS-based delivery can provide consistent therapeutic levels, potentially improving outcomes in diseases like retinal vein occlusion and posterior uveitis.[6]

3.2.3. Hydrogels and contact lens-based delivery

Hydrogels and contact lenses are being developed as innovative platforms for ocular drug delivery, offering continuous drug release and improved patient comfort.[7]

a).**Hydrogels:**Hydrogels are three-dimensional, hydrophilic polymer networks capable of absorbing significant amounts of water. They can be loaded with drugs and applied to the ocular surface, providing a sustained release over extended periods. This method has shown promise in delivering anti-inflammatory and anti-glaucoma medications. Hydrogels loaded with anti-inflammatory drugs have been used post-surgery to manage inflammation and pain. Clinical studies have shown that these hydrogels can provide sustained drug release, improving patient comfort and reducing the need for frequent eye drop administration.[8]

b).**Drug-Embedded Contact Lenses:** These lenses are designed to release drugs continuously as they are worn. They provide a convenient and non-invasive method for drug delivery, particularly for chronic conditions like glaucoma. Studies have demonstrated that drug-embedded contact lenses can maintain therapeutic drug levels in the tear film for extended durations, reducing the need for frequent eye drop administration. Drug-embedded contact lenses have been tested in clinical trials for glaucoma management. These lenses release drugs gradually over time, maintaining consistent therapeutic levels and effectively lowering IOP with fewer side effects compared to traditional eye drops.[9]

3.2.4. Microneedle technology

Microneedle technology offers a minimally invasive approach to deliver drugs directly to ocular tissues, bypassing traditional barriers and enhancing drug efficacy.[10]

a).**Microneedle Arrays:** These are tiny needles arranged on a patch that can penetrate the outer layers of the eye without reaching nerve-rich regions, minimizing discomfort. Microneedle patches can be used to deliver drugs into the cornea, sclera, or even the posterior segment, offering a versatile platform for various ocular therapies. Microneedle arrays have been used to deliver drugs directly to the retina, bypassing the ocular barriers that limit traditional methods. Clinical trials have shown that microneedle-based delivery can achieve higher drug concentrations in the retina, improving outcomes in conditions like diabetic retinopathy and retinal vein occlusion.[11]

b).**Biodegradable Microneedles:** These microneedles dissolve after penetrating the ocular tissue, releasing the drug payload in a controlled manner. This technology is particularly useful for delivering drugs to treat posterior segment diseases, such as macular degeneration and diabetic retinopathy. Biodegradable microneedles have also been utilized for delivering drugs to the cornea, providing controlled release and improving treatment efficacy for conditions such as corneal neovascularization and keratitis. A study by Shi H, et al reported rapid corneal healing by microneedles leading to significant improvements in disease resolution and patient satisfaction.[12]

3.2.5. Gene therapy vectors

Gene therapy represents a frontier in treating inherited retinal diseases by addressing the underlying genetic defects. Recent advancements in gene therapy vectors have shown promising results .

a).**Viral vectors:** Adeno-associated viruses (AAV) are commonly used vectors for delivering therapeutic genes to retinal cells. Clinical trials have demonstrated the efficacy of AAV-based gene therapies in treating conditions like Leber's congenital amaurosis (LCA) and choroideremia, with sustained improvements in vision. Sai H, et al reported AAV-mediated gene therapy in retinal organoids modeling AIPL1-associated LCA_4 restoring visual function.[13,14]

b).**Non-viral vectors:** Non-viral vectors, including nanoparticles and liposomes, offer a safer alternative to viral vectors, with reduced immunogenicity and toxicity. Gene therapy using non-viral vectors has been explored for choroideremia, a degenerative retinal disease. Early clinical trials indicate that gene replacement therapy can slow disease progression and preserve vision, offering hope for long-term management of this condition.[15] Research is on going to optimize these vectors for efficient gene delivery to retinal cells, aiming to treat a broader range of genetic ocular diseases.

The innovations in ocular drug delivery systems hold great potential to overcome the limitations of traditional methods, offering enhanced drug bioavailability, sustained release, and improved patient compliance. As research progresses, these advanced delivery systems are expected to significantly impact the treatment and management of various ocular diseases, ultimately improving patient outcomes.

4. Challenges and future directions

While the advancements in ocular drug delivery systems have shown great promise, several challenges need to be addressed to optimize their clinical application and ensure widespread adoption. The challenges and potential future directions for research and development in this field are as under.

4.1. Challenges

a).**Biocompatibility and Toxicity:** Ensuring the biocompatibility and safety of new drug delivery systems is paramount. Nanoparticles, implants, and other devices must not induce adverse immune responses or toxicity in ocular tissues. Long-term studies are required to fully understand the biocompatibility of these materials and their degradation products.

b).**Drug Stability and Release Kinetics:** Achieving controlled and sustained drug release while maintaining drug stability is a significant challenge. Variability in release kinetics can lead to suboptimal therapeutic outcomes. Advances in materials science and engineering are needed to develop delivery systems that provide consistent and predictable drug release profiles.

c).**Patient Compliance and Acceptance:** Innovative drug delivery systems must be designed with patient compliance in mind. Devices that are uncomfortable or require complex administration procedures may not be well-received by patients. Ensuring ease of use and comfort is critical for the success of these technologies.

d).**Regulatory and Manufacturing Hurdles:** Bringing new ocular drug delivery systems to market involves navigating complex regulatory pathways. Ensuring that these systems meet stringent safety and efficacy standards is challenging. Additionally, scaling up the manufacturing processes for these advanced technologies can be difficult and costly.

e).**Cost and Accessibility:** The development and production of advanced ocular drug delivery systems can be expensive, which may limit their accessibility to patients. Strategies to reduce costs without compromising quality are essential to ensure that these innovations benefit a broad patient population.

4.2. Future Directions

a).**Personalized Medicine:** The integration of personalized medicine approaches with ocular drug delivery systems holds great promise. Tailoring drug delivery based on individual patient characteristics, such as genetic profiles and disease progression, can enhance therapeutic outcomes. Advances in biomarker research and genomics will play a crucial role in this area.

b).**Smart Drug Delivery Systems:** The development of "smart" drug delivery systems that respond to physiological triggers or provide feedback on drug levels is an exciting frontier. These systems could adjust drug release rates in real-time based on the patient's needs, optimizing therapeutic efficacy and minimizing side effects.

c).**Gene and Cell Therapies:** Continued advancements in gene and cell therapies offer the potential to treat previously untreatable ocular conditions. Developing efficient delivery systems for these therapies is critical. Viral and non-viral vectors, as well as stem cell delivery mechanisms, are areas of active research.

d).**Nanotechnology Advancements:** Further innovations in nanotechnology could enhance the precision and efficacy of ocular drug delivery. Multifunctional nanoparticles capable of targeting specific cell types, providing imaging capabilities, and delivering combination therapies are under investigation.

e).**Regenerative Medicine:** Incorporating regenerative medicine approaches with drug delivery systems may offer new therapeutic options for ocular diseases. Biodegradable scaffolds and hydrogels that release growth factors or stem cells to repair damaged tissues are promising avenues for research.

f).**Collaboration and Interdisciplinary Research:** Addressing the challenges in ocular drug delivery will require collaboration across multiple disciplines, including materials science, pharmacology, ophthalmology, and bioengineering.

5. Conclusion

In recent years, innovations in ocular drug delivery systems have significantly advanced the treatment of various ocular diseases. Traditional methods such as eye drops, ointments, and intravitreal injections have limitations, including poor bioavailability, frequent administration, and patient non-compliance. The emergence of novel delivery systems, including nanoparticles, microneedles, sustained-release implants, and gene therapy vectors, offers solutions to these challenges. These innovations provide controlled and sustained drug release, improved drug stability, and targeted delivery to specific ocular tissues, resulting in enhanced therapeutic outcomes and reduced side effects.

The implications of these advancements are profound for both clinicians and patients. For clinicians, the availability of more effective and less invasive delivery systems can simplify treatment regimens and improve patient management. For patients, these innovations translate to better disease control, fewer side effects, and improved quality of life. The future of ocular drug delivery lies in further refining these innovative approaches and exploring new frontiers. Personalized medicine, smart drug delivery systems, and regenerative therapies represent exciting avenues for future research and development.

In conclusion, the landscape of ocular drug delivery is undergoing a transformative shift. While significant progress has been made, ongoing research and collaboration across disciplines are essential to overcome current challenges and fully realize the potential of these innovative technologies. The continued development of biocompatible, effective, and patient-friendly delivery systems will enhance the management of ocular diseases, ultimately improving patient outcomes and quality of life.

6. Source of Funding

None.

7. Conflict of Interest

None.

References

1. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. *Ophthalmology*. 2006;113(6):1020–7.
2. Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V. Correction to: An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. *AAPS PharmSciTech*. 2024;20(7):281.
3. Monte MD, Cammalleri M, Pezzino S, Corsaro R, Pescosolido N, Bagnoli P. Hypotensive Effect of Nanomicellar Formulation of Melatonin and Agomelatine in a Rat Model: Significance for Glaucoma Therapy. *Diagnostics (Basel)*. 2020;10(3):138.
4. Youssef A, Cai C, Dudhipala N, Majumdar S. Design of Topical Ocular Ciprofloxacin Nanoemulsion for the Management of Bacterial Keratitis. *Pharmaceuticals (Basel)*. 2021;14(3):210.
5. Dias JO, Nunes RP, Goldhardt R. New Drugs and New Posterior Delivery Methods in CME. *Curr Ophthalmol Rep*. 2017;5(2):160–8.
6. Molaei A, Karamzadeh V, Safi S, Esfandiari H, Dargahi J, Khosravi MA. Upcoming Methods and Specifications of Continuous Intraocular Pressure Monitoring Systems for Glaucoma. *J Ophthalmic Vis Res*. 2018;13(1):66–71.
7. Fang G, Yang X, Wang Q, Zhang A, Tang B. Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases. *Mater Sci Eng C Mater Biol Appl*. 2021;127:112212.
8. Yu C, Xu J, Heidari G, Jiang H, Shi Y, Wu A, et al. Injectable hydrogels based on biopolymers for the treatment of ocular diseases. *Int J Biol Macromol*. 2024;269(Pt 1):132086.
9. Zhao L, Song J, Du Y, Ren C, Guo B, Bi H. Therapeutic applications of contact lens-based drug delivery systems in ophthalmic diseases. *Drug Deliv*. 2023;30(1):2219419.
10. Glover K, Mishra D, Gade S, Vora LK, Wu Y, Paredes AJ, et al. Microneedles for advanced ocular drug delivery. *Adv Drug Deliv Rev*. 2023;201:115082.
11. Shi H, Huai S, Wei H, Xu Y, Lei L, Chen H, et al. Dissolvable hybrid microneedle patch for efficient delivery of curcumin to reduce intraocular inflammation. *Int J Pharm*. 2023;643:123205.
12. Shi H, Zhou J, Wang Y, Zhu Y, Lin D, Lei L, et al. A Rapid Corneal Healing Microneedle for Efficient Ocular Drug Delivery. *Small*. 2022;18(4):2104657.
13. Sai H, Ollington B, Rezek FO, Chai N, Lane A, Georgiadis T. Effective AAV-mediated gene replacement therapy in retinal organoids modeling AIPL1-associated LCA4. *Mol Ther Nucleic Acids*. 2024;35(1):102148.
14. Whitehead M, Osborne A, Yu-Wai-Man P, Martin K. Humoral immune responses to AAV gene therapy in the ocular compartment. *Biol Rev Camb Philos Soc*. 2021;96(4):1616–44.
15. Battu R, Ratra D, Gopal L. Newer therapeutic options for inherited retinal diseases: Gene and cell replacement therapy. *Indian J Ophthalmol*. 2022;70(7):2316–25.

Author biography

Sumit Goyal, Assistant Professor https://orcid.org/0009-0008-8678-0680

Pranjali Dwivedi, Assistant Professor https://orcid.org/0000-0002-1671-541X

Jaya Kaushik, Professor https://orcid.org/0000-0002-6058-4875

Mayank Jhanwar, Assistant Professor https://orcid.org/0000-0001-8257-32 I3

Ankita Singh, Assistant Professor https://orcid.org/0000-0002-81 36-6375

Anushree C M, Assistant Professor https://orcid.org/0009-0005-5469-8509

Cite this article: Goyal S, Dwivedi P, Kaushik J, Jhanwar M, Singh A, C M A. Innovations in ocular drug delivery. *Southeast Asian J Health Prof* 2024;7(3):59-64.